drug

tibulizumab

1 story · latest Aug 11, 2026

Status: Investigational
Code: ZB-106
Trials: 1 registered trial in coverage

Relationships

Developed by Zura Bio Inc

Timeline

Zura Bio reports Q2 2026 results, completes enrollment in two tibulizumab trials

Aug 11Clinical readouttibulizumab Zura Bio Inc

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.